Emergent Biosolutions Stock Fundamentals
| EBS Stock | USD 5.50 0.21 3.68% |
Emergent Biosolutions fundamentals help investors to digest information that contributes to Emergent Biosolutions' financial success or failures. It also enables traders to predict the movement of Emergent Stock. The fundamental analysis module provides a way to measure Emergent Biosolutions' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Emergent Biosolutions stock.
At this time, Emergent Biosolutions' Depreciation And Amortization is comparatively stable compared to the past year. Interest Expense is likely to gain to about 45 M in 2024, despite the fact that Operating Income is likely to grow to (181.4 M). Emergent | Select Account or Indicator |
Emergent Biosolutions Company Operating Margin Analysis
Emergent Biosolutions' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Emergent Biosolutions Operating Margin | 0.13 % |
Most of Emergent Biosolutions' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Emergent Biosolutions is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Emergent Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Emergent Biosolutions has an Operating Margin of 0.1325%. This is 100.38% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The operating margin for all United States stocks is 102.4% lower than that of the firm.
Emergent Biosolutions Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Emergent Biosolutions's current stock value. Our valuation model uses many indicators to compare Emergent Biosolutions value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Emergent Biosolutions competition to find correlations between indicators driving Emergent Biosolutions's intrinsic value. More Info.Emergent Biosolutions is rated # 2 in return on equity category among related companies. It is rated # 3 in return on asset category among related companies . At this time, Emergent Biosolutions' Return On Equity is comparatively stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Emergent Biosolutions by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Emergent Biosolutions' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Emergent Biosolutions' earnings, one of the primary drivers of an investment's value.Emergent Biosolutions' Earnings Breakdown by Geography
Emergent Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Emergent Biosolutions' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Emergent Biosolutions could also be used in its relative valuation, which is a method of valuing Emergent Biosolutions by comparing valuation metrics of similar companies.Emergent Biosolutions is currently under evaluation in operating margin category among related companies.
Emergent Biosolutions ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Emergent Biosolutions' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Emergent Biosolutions' managers, analysts, and investors.Environmental | Governance | Social |
Emergent Fundamentals
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.0038 | ||||
| Profit Margin | (0.48) % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 1.14 B | ||||
| Shares Outstanding | 52.4 M | ||||
| Shares Owned By Insiders | 1.88 % | ||||
| Shares Owned By Institutions | 74.78 % | ||||
| Number Of Shares Shorted | 7.13 M | ||||
| Price To Earning | 1.67 X | ||||
| Price To Book | 0.17 X | ||||
| Price To Sales | 0.10 X | ||||
| Revenue | 1.12 B | ||||
| Gross Profit | 290.1 M | ||||
| EBITDA | (34.4 M) | ||||
| Net Income | (223.8 M) | ||||
| Cash And Equivalents | 642.6 M | ||||
| Cash Per Share | 7.28 X | ||||
| Total Debt | 1.41 B | ||||
| Debt To Equity | 0.56 % | ||||
| Current Ratio | 3.92 X | ||||
| Book Value Per Share | 12.67 X | ||||
| Cash Flow From Operations | (34.1 M) | ||||
| Short Ratio | 7.01 X | ||||
| Earnings Per Share | (10.97) X | ||||
| Price To Earnings To Growth | 1.55 X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 1.6 K | ||||
| Beta | 1.24 | ||||
| Market Capitalization | 299.21 M | ||||
| Total Asset | 3.17 B | ||||
| Retained Earnings | 734 M | ||||
| Working Capital | 28.2 M | ||||
| Current Asset | 537.41 M | ||||
| Current Liabilities | 99.61 M | ||||
| Net Asset | 3.17 B |
About Emergent Biosolutions Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Emergent Biosolutions's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Emergent Biosolutions using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Emergent Biosolutions based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 30.4 M | 28.1 M | |
| Total Revenue | 1.3 B | 1.4 B | |
| Cost Of Revenue | 797.8 M | 837.6 M | |
| Stock Based Compensation To Revenue | 0.02 | 0.03 | |
| Sales General And Administrative To Revenue | 0.30 | 0.31 | |
| Research And Ddevelopement To Revenue | 0.10 | 0.1 | |
| Capex To Revenue | (0.05) | (0.05) | |
| Revenue Per Share | 20.49 | 21.52 | |
| Ebit Per Revenue | (0.16) | (0.16) |
Pair Trading with Emergent Biosolutions
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Emergent Biosolutions position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Emergent Biosolutions will appreciate offsetting losses from the drop in the long position's value.Moving against Emergent Stock
| 0.41 | VALN | Valneva SE ADR | PairCorr |
The ability to find closely correlated positions to Emergent Biosolutions could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Emergent Biosolutions when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Emergent Biosolutions - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Emergent Biosolutions to buy it.
The correlation of Emergent Biosolutions is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Emergent Biosolutions moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Emergent Biosolutions moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Emergent Biosolutions can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Emergent Biosolutions Piotroski F Score and Emergent Biosolutions Altman Z Score analysis. For more information on how to buy Emergent Stock please use our How to Invest in Emergent Biosolutions guide.Note that the Emergent Biosolutions information on this page should be used as a complementary analysis to other Emergent Biosolutions' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for Emergent Stock analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |
Is Emergent Biosolutions' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Emergent Biosolutions. If investors know Emergent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Emergent Biosolutions listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.022 | Earnings Share (10.97) | Revenue Per Share 22.928 | Quarterly Revenue Growth 0.828 | Return On Assets (0) |
The market value of Emergent Biosolutions is measured differently than its book value, which is the value of Emergent that is recorded on the company's balance sheet. Investors also form their own opinion of Emergent Biosolutions' value that differs from its market value or its book value, called intrinsic value, which is Emergent Biosolutions' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Emergent Biosolutions' market value can be influenced by many factors that don't directly affect Emergent Biosolutions' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Emergent Biosolutions' value and its price as these two are different measures arrived at by different means. Investors typically determine if Emergent Biosolutions is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Emergent Biosolutions' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.